{
    "company_name": "ALTERITY THERAPEUTICS LIMITED",
    "address": "Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053",
    "summary": "The Company's business is the development of therapeutic drugs for age-related diseases.",
    "details": "The Company's business is the development of therapeutic drugs for age-related diseases.",
    "website": "http://www.alteritytherapeutics.com",
    "stock_code": "ATH",
    "links": "['https://alteritytherapeutics.com', '#search', '#navigation', 'https://alteritytherapeutics.com/pipeline/', 'https://alteritytherapeutics.com/the-science/', 'https://alteritytherapeutics.com/about-us/', 'https://alteritytherapeutics.com/investor-overview/', 'https://alteritytherapeutics.com/investor-overview/', 'https://alteritytherapeutics.com/investor-overview/press-releases/', 'https://alteritytherapeutics.com/investor-overview/asx-announcements/', 'https://alteritytherapeutics.com/investor-overview/events-and-presentations/', 'https://alteritytherapeutics.com/investor-overview/corporate-governance/', 'https://alteritytherapeutics.com/investor-overview/financial-information/', 'https://alteritytherapeutics.com/investor-overview/analyst-coverage/', '/contact-us', '#', 'https://alteritytherapeutics.com/about-us/', 'https://alteritytherapeutics.com/pipeline/', 'https://alteritytherapeutics.com/investor-centre/news/2024/04/10/alterity-therapeutics-to-present-new-data-on-ath434-at-the-world-orphan-drug-congress-usa-2024/', 'https://alteritytherapeutics.com/investor-centre/news/2024/04/10/alterity-therapeutics-to-present-new-data-on-ath434-at-the-world-orphan-drug-congress-usa-2024/', 'https://alteritytherapeutics.com/investor-centre/news/2024/03/26/alterity-therapeutics-receives-a-3-9-million-research-development-tax-incentive-refund/', 'https://alteritytherapeutics.com/investor-centre/news/2024/03/26/alterity-therapeutics-receives-a-3-9-million-research-development-tax-incentive-refund/', 'https://alteritytherapeutics.com/investor-centre/news/2024/02/23/alterity-therapeutics-raises-3-25-m-aud-in-placement/', 'https://alteritytherapeutics.com/investor-centre/news/2024/02/23/alterity-therapeutics-raises-3-25-m-aud-in-placement/', 'https://alteritytherapeutics.com/investor-overview/press-releases/', 'https://www.linkedin.com/company/19106782', 'https://www.facebook.com/alteritytherapeutics', 'https://twitter.com/AlterityT', 'https://alteritytherapeutics.com/pipeline/', 'https://alteritytherapeutics.com/the-science/', 'https://alteritytherapeutics.com/about-us/', 'https://alteritytherapeutics.com/investor-centre-2/', 'https://alteritytherapeutics.com/investor-centre-2/news/', 'https://alteritytherapeutics.com/careers/', 'https://alteritytherapeutics.com/privacy-policy/']",
    "images": "https://alteritytherapeutics.com/wp-content/uploads/logos/AlterityThera-BlueType-Horizontal@3x.png, https://alteritytherapeutics.com/wp-content/uploads/logos/AlterityThera-White-Horizontal@3x.png, https://alteritytherapeutics.com/wp-content/uploads/home.jpg, https://alteritytherapeutics.com/wp-content/uploads/hands-cta.png, /wp-content/uploads/logos/alterity-therapeutics-weboptim.svg",
    "company_logo_link": "https://alteritytherapeutics.com/wp-content/uploads/logos/AlterityThera-BlueType-Horizontal@3x.png"
}